Stay on forever or quit cold: that's how the long-term GLP-1 question usually gets framed. There's a third path in between, and it now has real trial evidence behind it.
Three long-term paths
You can stay on your current dose, stop entirely, or taper to a lower dose that still works. Our discussion guide on talking to your doctor about stopping or tapering treatment covers how to raise this conversation; this guide covers how the dosing side of that decision actually works.
What the research suggests about dose reduction vs. stopping
A 2026 clinical trial (SURMOUNT-MAINTAIN) directly compared the three paths. After 60 weeks of weight loss on their highest tolerated dose of tirzepatide (10 or 15 mg), participants were randomly assigned to continue that dose, reduce to 5 mg, or switch to placebo for another year. At week 112, total weight change from baseline was −21.9% on the full dose, −16.6% on 5 mg, and −9.9% on placebo, and rescue treatment for regaining at least half of the lost weight was needed by 8%, 25%, and 67% of each group respectively (Horn et al., The Lancet, 2026, DOI (external link)). Both continuing at the full dose and reducing to 5 mg maintained significantly more weight loss than switching to placebo, though the full dose maintained more than the reduced dose. So a reduced maintenance dose is a real middle path: clearly better than stopping, and somewhat short of staying put.
Who was studied, and who paid for it. The trial ran at 20 US sites and enrolled 441 adults with an average BMI of about 40 and an average weight of 114 kg; about two-thirds were women and two-thirds were White. It was funded by Eli Lilly, which makes tirzepatide, and seven of its thirteen authors are Lilly employees. It tested one reduced dose (5 mg) for one year. It did not test 10 mg as a step-down, and it did not test semaglutide, for which no equivalent dose-reduction trial exists yet. If you're taking Wegovy or Ozempic, this evidence applies to you only by analogy. Our guide to the key GLP-1 clinical trials lists this trial alongside the others, with who funded each one.
A less-studied variation is keeping the same dose but spacing injections further apart, such as every 10 or 14 days. It has no randomized trial behind it yet; see stretching your GLP-1 dose past 7 days for what the early evidence shows.
A newer option: switching to a pill
A separate 2026 trial tested a different route off the full-dose injection. People who had lost weight on injectable tirzepatide or semaglutide switched to the daily GLP-1 pill orforglipron (Foundayo). After a year, those coming off tirzepatide had kept about 75% of their weight loss and those coming off semaglutide about 79%, compared with 49% and 38% on a placebo pill (Aronne et al., Nature Medicine, 2026, DOI (external link)). That trial didn't include a group that stayed on the injection, so it shows that switching beats stopping, not that it matches continuing. If you're on Wegovy 2.4 mg, there's also an on-label pill route: as of September 2026 the Wegovy label allows switching to Wegovy 25 mg tablets, starting one week after your last injection. That switch wasn't part of the orforglipron trial. Our guide on switching from a GLP-1 injection to a pill covers both routes.
Why someone might choose to taper
Some people reach a goal weight or body composition and want to shift from active loss to maintenance, where a lower dose may be enough to hold results. Others have side effects and would trade some effect for more comfortable days without giving up the medication's benefit entirely. And some want to lean more on diet and exercise for maintenance, with a lower dose as a supportive bridge.
How this decision typically gets made
It's a gradual, monitored process. Your prescriber will usually track how you respond to a lower dose (weight trend, appetite, any symptom changes) before confirming it as your new stable point. It works much like titrating up, in reverse.
The bottom line
Tapering to a lower, still-active maintenance dose has randomized trial evidence behind it, at least for tirzepatide. It isn't free: in that trial about 1 in 4 people who stepped down regained at least half of their loss, against about 1 in 12 who stayed on the full dose. It's worth discussing with your prescriber if your goals, side effect tolerance, or life circumstances change, along with what you'd treat as the signal to step back up. If you're weighing stopping altogether, our guide on stopping a GLP-1: tapering, weight regain, and restarting safely covers what the withdrawal evidence shows and how restarting works.
Study findings above are attributed to their authors and were located via PubMed.
This is general education, not medical advice. Decisions about tapering or your maintenance dose belong with your prescriber.